COMMUNIQUÉS West-GlobeNewswire

Six-month interim report (Q2) 2025 (unaudited)
21/08/2025
ALK delivers 12% organic revenue growth with operating profit up 41% in Q2 Q2 results exceeded expectations, driven by an improved momentum for tablets and adrenaline autoinjectors. Sales in Europe were ahead of plan, [...]
Interim report H1 2025
21/08/2025
9% organic sales growth in H1 and FY outlook range narrowed to 6-8% Ester Baiget, President & CEO: “I’m very pleased with 9% organic sales growth in the first half of the year. Demand for our biosolutions is strong [...]
Telix 2025 Half-Year Results: Strong commercial performance enables investment for long-term growth
21/08/2025
MELBOURNE, Australia and INDIANAPOLIS, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces its financial results for the half-year ended 30 June 2025. All [...]
Latest breakthrough in Type 1 diabetes treatment: Chinese medical team enables 24 patients to discontinue insulin use
21/08/2025
SHENZHEN, China, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Recently, Professor An Chiying and her medical team at Shenzhen Hengsheng Hospital, China, announced a groundbreaking achievement: since June 2024, they have [...]
NurExone Biologic Announces Preclinical Evidence of Structural Repair in Injured Spinal Cord Tissue following ExoPTEN Treatment
20/08/2025
C$0.78 Million Private Placement Successfully Closed TORONTO and HAIFA, Israel, Aug. 20, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“ NurExone ” or the “ Company ”) is pleased [...]
Sana Biotechnology Announces Closing of Full Exercise of Underwriters’ Option to Purchase Additional Shares
20/08/2025
SEATTLE, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (Nasdaq: SANA) (“Sana”), a company focused on changing the possible for patients through engineered cells, today announced that it has closed the sale [...]
Outset Medical to Present at the 23rd Annual Morgan Stanley Global Healthcare Conference
20/08/2025
SAN JOSE, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, [...]
Olema Oncology to Participate in Upcoming Investor Conferences
20/08/2025
SAN FRANCISCO, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and [...]
Onco360® Has Been Selected as a Specialty Pharmacy Partner for HERNEXEOS® (zongertinib)
20/08/2025
LOUISVILLE, K.Y., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Onco360 ® , the nation’s leading independent Specialty Pharmacy, has been selected as a pharmacy partner by Boehringer Ingelheim for Hernexeos ® (Zongertinib). The [...]
BioAge Labs to Present at Upcoming Investor Conferences
20/08/2025
EMERYVILLE, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases [...]
Larkspur Biosciences Announces Discovery of LRK-4189, a First-in-Class Degrader of the Lipid Kinase PIP4K2C, for the Treatment of Microsatellite Stable (MSS) Colorectal Cancer at the ACS Fall 2025 Meeting
20/08/2025
First-in-human, Phase 1 Study of LRK-4189 to Begin in the Fourth Quarter CAMBRIDGE, Mass., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Larkspur Biosciences, a company pioneering a new wave in cancer therapy that destroys tumors [...]
Ascentage Pharma Reports 2025 Interim Unaudited Six Months Financial Results and Business Updates
21/08/2025
Product sales from Olverembatinib in the first half of 2025 increased 93% year-over-year to US$30.3 million (RMB217.4 million), primarily attributable to the expansion of NRDL coverage Commenced commercial sales of [...]
2030 financial targets announced: Organic sales growth acceleration, margin expansion and ROIC improvement
20/08/2025
COPENHAGEN, Denmark - August 20, 2025. Novonesis today announces its ‘GROW’ strategy and long-term targets for the strategy period until 2030 focusing on an acceleration of the core business and significant re- [...]
APIX Biosciences NV announces new advances in Honeybee Nutrition
20/08/2025
WINGENE, Belgium, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Belgian agri-technology company APIX Biosciences NV, active in Europe and the United States, proudly announces the publication in Nature, by APIX Biosciences’ [...]
Zealand Pharma major shareholder announcement: Van Herk Investments B.V.
20/08/2025
Company announcement – No. 19 / 2025 Zealand Pharma major shareholder announcement: Van Herk Investments B.V. Copenhagen, Denmark, August 20, 2025 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20045078), a [...]
Invivyd Announces Proposed Public Offering of Common Stock
20/08/2025
WALTHAM, Mass., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Invivyd) (Nasdaq: IVVD) today announced that it has commenced an underwritten public offering of shares of its common stock. In addition, Invivyd intends [...]
Rhythm Pharmaceuticals Announces FDA Acceptance of sNDA for Setmelanotide in Acquired Hypothalamic Obesity
20/08/2025
– U.S. Food and Drug Administration accepts sNDA for filing with priority review; sets PDUFA goal date of December 20, 2025 -- – European Medicines Agency accepts and validates submission for Type II variation MAA for [...]
Glaucoma Research Foundation Launches Treatment Accelerator with Transformative $5 Million Gift
20/08/2025
Largest-ever gift to Glaucoma Research Foundation moves vision-restoration discoveries from lab to clinic faster than ever before SAN FRANCISCO, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Glaucoma Research Foundation is proud to [...]
EYLEA HD® (aflibercept) Injection 8 mg Applications for Expanded U.S. Label and Prefilled Syringe Receive FDA Review Period Extension
20/08/2025
TARRYTOWN, N.Y., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has extended the target action dates to the fourth [...]

Pages